

Pioneering Precision Medicine for Neurodegenerative Diseases



Nationality:



Founded:

2018

After a decade of research, AgentT has built HORIZON™, a proprietary multiomic platform designed to predict and monitor neurodegenerative diseases.

Leveraging patented biomarkers, proprietary targeted mass spectrometry methods, and AI-based software, AgentT is developing highly specific blood tests to predict disease progression, with first applications in Alzheimer's disease.

Co-founders



Baptiste Billoir
HEC Paris



Jérôme Braudeau
PhD in Neuroscience

€8M

Already Raised
(Including €3.5M Non-Dilutive)

Contact: baptiste.billoir@agent-biotech.com
Website: www.agent-biotech.com



HORIZON™: Proprietary Multiomic Platform for Age-Related Diseases

- Exclusive ability to **monitor 8 key biological pathways** (41 metabolites, 44 proteins) involved in major age-related diseases, through targeted mass spectrometry methods.
- **Potential for multiple indications and applications**, including diagnostics, companion diagnostics, and therapeutic targets – **Expected revenue by Q3 2026.**



B-HEALED™ & B-AHEAD™: First HORIZON™-Based Blood Tests for Predicting Alzheimer's

- **Predict progression to Alzheimer's dementia symptoms** in cognitively unimpaired and impaired individuals, with **3x fewer false positives** than current tests on the market.
- Validated in a 1st multicenter retrospective study involving 632 individuals (USA, Europe, Australia).



Proprietary Database from 5,000+ Plasma Samples Across 3 Continents

- A unique database with **absolute concentrations of 85 patented biomarkers from 5,000+ retrospective human plasma samples** sourced from 20+ independent cohorts across the US, Europe, and Australia enriched with **longitudinal clinical follow-up data of up to 10+ years.**



Strategic Partnership with INOVIE to Validate First HORIZON™ Applications

- Ongoing **4,200-participant retrospective pivotal clinical validation study** for B-HEALED™ and B-AHEAD™, **supporting future FDA approval.**
- Provides a scalable route to commercialization through established clinical laboratory workflows.



Phased Market-Access Strategy from Clinical Trials to Broad Commercial Rollout

- Initial commercialization through **pharma and nutrition-sponsored clinical trials** using HORIZON™, followed by B-HEALED™ and B-AHEAD™ after clinical validation.
- Following FDA approval, B-HEALED™ targets an **\$8.5B market** of MCI patients at risk of Alzheimer's.

MCI: Mild Cognitive Impairment